Alkermes leaps on positive Ph III results for aripiprazole lauroxil for schizophrenia

9 April 2014

US biotech firm Alkermes (Nasdaq: ALKS) saw its shares spike on Tuesday, after it announced positive top-line results from a randomized, double-blind, placebo-controlled Phase III clinical trial of aripiprazole lauroxil in patients with schizophrenia. Although the shares closed up just 2.4% at $42.08, they rose to $45.48 earlier in the day.

Patients treated once monthly with either 441mg or 882mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441mg, p<0.001 aripiprazole lauroxil 882mg), which was the pre-specified primary endpoint in the study.

Regulatory filing planned for third quarter

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK